

Dr Ali Manouchehrinia is an assistant professor in neuro and genetic epidemiology in the Department of Clinical Neuroscience, Karolinska Institutet (KI). He is part of a multidisciplinary research group interested in different aspects of epidemiology of MS.

At Karolinska Institutet, He been part of a multidisciplinary research group interested in different aspects of epidemiology of Multiple Sclerosis (MS). His research addresses important questions facing patients, physicians and researchers with an aim to forge understanding of mechanisms behind progression of physical disability and cognitive impairment in MS. His aim has been to foster cross-disciplinary collaborations between researchers, patients and clinicians through several national and international projects. The objective of his research at KI is focused around three aims:

- Explore **genetic, environmental, clinical** and **lifestyle** risk factors for MS disability accumulation;
- Characterise disability progression and its variation across sociodemographic and clinical subgroups;
- Develop and validate more accurate and responsive methods of measuring MS disability using linked nationwide information.

## Background

INSTITUTION AND LOCATION	DEGREE	FIELD OF STUDY
Tehran University of Medical Sciences, Iran	BSc	Radiology
University of Dundee, UK	MSc	Human Anatomy and identification
University of Nottingham, UK	PhD	Neuroepidemiology
Karolinska Institutet, Sweden	Postdoctoral	Neuroepidemiology
Karolinska Institutet, Sweden	Assistant Professor	Genetic Epidemiology

## Publications

For the full list see: <https://www.ncbi.nlm.nih.gov/pubmed/?term=manouchehrinia>

1. Kavaliunas A, Danylaite Karrenbauer V, Gyllensten H, **Manouchehrinia A**, Glaser A, Olsson T, Alexanderson K, Hillert J. Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability. Multiple sclerosis (Houndmills, Basingstoke, England) 2019 25;1 104-112

2. Alrouji M, **Manouchehrinia A**, Gran B, Constantinescu CS. Effects of cigarette smoke on immunity, neuroinflammation and multiple sclerosis. *Journal of neuroimmunology* 2019 329; 24-34
3. Crielaard L, Kavaliunas A, Ramanujam R, Olsson T, Hillert J, Stridh P, Kockum I, **Manouchehrinia A**. Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study. *Journal of neurology, neurosurgery, and psychiatry* 2019 ;
4. Song J, Westerlind H, McKay KA, Almqvist C, Stridh P, Kockum I, Hillert J, **Manouchehrinia A**. Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study. *Journal of neurology* 2019 266;2 481-486
5. **Manouchehrinia A**, Hedstrom AK, Alfredsson L, Olsson T, Hillert J, Ramanujam R. Association of Pre-Disease Body Mass Index With Multiple Sclerosis Prognosis. *FRONTIERS IN NEUROLOGY* 2018 9; 232-
6. Freilich J, **Manouchehrinia A**, Trusheim M, Baird LG, Desbiens S, Berndt E, Hillert J. Characterization of annual disease progression of multiple sclerosis patients: A population-based study. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2018 24;6 786-794
7. Bedri SK, Fink K, **Manouchehrinia A**, Lundström W, Kockum I, Olsson T, Hillert J, Glaser A. Multiple sclerosis treatment effects on plasma cytokine receptor levels. *Clinical immunology (Orlando, Fla.)* 2018 187; 15-25
8. **Manouchehrinia A**, Zhu F, Piani-Meier D, Lange M, Silva DG, Carruthers R, Glaser A, Kingwell E, Tremlett H, Hillert J. Predicting risk of secondary progression in multiple sclerosis: A nomogram. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2018 ; 1352458518783667-
9. Dunn N, Juto A, Ryner M, **Manouchehrinia A**, Piccoli L, Fink K, Piehl F, Fogdell-Hahn A. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2018 24;9 1224-1233
10. Heydarpour P, **Manouchehrinia A**, Beiki O, Mousavi SE, Abdolalizadeh A, -Lakeh MM, Sahraian MA. Smoking and worsening disability in multiple sclerosis: A meta-analysis. *Acta neurologica Scandinavica* 2018 138;1 62-69
11. Tanasescu R, Constantinescu CS, Tench CR, **Manouchehrinia A**. Smoking Cessation and the Reduction of Disability Progression in Multiple Sclerosis: A Cohort Study. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco* 2018 20;5 589-595
12. **Manouchehrinia A**, Westerlind H, Kingwell E, Zhu F, Carruthers R, Ramanujam R, Ban M, Glaser A, Sawcer S, Tremlett H, Hillert J. Age Related Multiple Sclerosis Severity Score: Disability ranked by age. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2017 23;14 1938-1946
13. **Manouchehrinia A**, Beiki O, Hillert J. Clinical course of multiple sclerosis: A nationwide cohort study. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2017 23;11 1488-1495
14. Kavaliunas A, **Manouchehrinia A**, Stawiarz L, Ramanujam R, Agholme J, Hedström AK, Beiki O, Glaser A, Hillert J. Importance of early treatment initiation in the clinical course of multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2017 23;9 1233-1240

15. Kavaliunas A, **Manouchehrinia A**, Danylaite Karrenbauer V, Gyllensten H, Glaser A, Alexanderson K, Hillert J. Income in Multiple Sclerosis Patients with Different Disease Phenotypes. *PLoS one* 2017 12;1 e0169460-
16. **Manouchehrinia A**, Tanasescu R, Kareem H, Jerca OP, Jabeen F, Shafei R, Breuer J, Neal K, Irving W, Constantinescu CS. Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. *Journal of neurovirology* 2017 23;6 839-844
17. Song J, Karrenbauer V, **Manouchehrinia A**, Almqvist C, Hillert J, Westerlind H. Similar familial risk in multiple sclerosis subgroups. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2017 23;13 1782-1785
18. Birkeldh U, **Manouchehrinia A**, Hietala MA, Hillert J, Olsson T, Piehl F, Kockum IS, Brundin L, Zahavi O, Wahlberg-Ramsay M, Brautaset R, Nilsson M. The Temporal retinal nerve Fiber layer Thickness is the Most important Optical coherence Tomography estimate in Multiple sclerosis. *FRONTIERS IN NEUROLOGY* 2017 8; 675-
19. MSBase Study Grp, Kalincik T, **Manouchehrinia A**, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Sanchez-Menoyo JL, Saladino ML, Barnett M, Hillert J, Butzkueven H. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. *BRAIN* 2017 140; 2426-2443
20. Westerlind H, Stawiarz L, Fink K, Hillert J, **Manouchehrinia A**. A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2016 22;8 1071-9
21. **Manouchehrinia A**, Tanasescu R, Tench CR, Constantinescu CS. Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. *JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY* 2016 87;3 324-31
22. Ramanujam R, Hedström AK, **Manouchehrinia A**, Alfredsson L, Olsson T, Bottai M, Hillert J. Effect of Smoking Cessation on Multiple Sclerosis Prognosis. *JAMA neurology* 2015 72;10 1117-23
23. **Manouchehrinia A**, Edwards LJ, Roshanifefat H, Tench CR, Constantinescu CS. Multiple sclerosis course and clinical outcomes in patients with comorbid asthma: a survey study. *BMJ open* 2015 5;5 e007806-
24. **Manouchehrinia A**, Weston M, Tench CR, Britton J, Constantinescu CS. Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. *JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY* 2014 85;10 1091-5
25. **Manouchehrinia A**, Tench CR, Maxted J, Bibani RH, Britton J, Constantinescu CS. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. *Brain : a journal of neurology* 2013 136;Pt 7 2298-304
26. **Manouchehrinia A**, Constantinescu CS. Cost-effectiveness of disease-modifying therapies in multiple sclerosis. *Current neurology and neuroscience reports* 2012 12;5 592-600
27. Bibani RH, Tench CR, George J, **Manouchehrinia A**, Palace J, Constantinescu CS. Reduced EDSS progression in multiple sclerosis patients treated with modafinil for three

years or more compared to matched untreated subjects. Multiple sclerosis and related disorders 2012 1;3 131-5

**Disclaimer**

Certain data included herein are derived from the Web of Science prepared by Clarivate Analytics, Inc. (Clarivate), Philadelphia, Pennsylvania, USA: Copyright Clarivate Analytics Group 2019. All rights reserved.

Data specified as deriving from MEDLINE/PubMed was updated 2019-03-16. NLM represents that its data were formulated with a reasonable standard of care. Except for this representation, NLM makes no representation or warranties, expressed or implied. This includes, but is not limited to, any implied warranty of merchantability or fitness for a particular purpose, with respect to the NLM data, and NLM specifically disclaims any such warranties and representations. All complete or parts of U.S. National Library of Medicine (NLM) records that are redistributed or retransmitted must be identified as being derived from NLM data.